Catalent Stock Forecast, Price & News

Catalent (NYSE:CTLT) Frequently Asked Questions

Is Catalent a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalent stock.
View analyst ratings for Catalent or view top-rated stocks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Catalent.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) posted its quarterly earnings data on Sunday, August, 29th. The company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.15. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.14 billion. Catalent had a net margin of 14.26% and a trailing twelve-month return on equity of 14.28%. The business's quarterly revenue was up 25.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 EPS.
View Catalent's earnings history.

How has Catalent's stock price been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTLT shares have increased by 198.1% and is now trading at $137.27.
View which stocks have been most impacted by COVID-19.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2022 earnings guidance on Monday, September, 27th. The company provided earnings per share (EPS) guidance of $3.230-$3.550 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.340. The company issued revenue guidance of $4.30 billion-$4.50 billion, compared to the consensus revenue estimate of $4.33 billion.

What price target have analysts set for CTLT?

10 brokerages have issued 1-year target prices for Catalent's shares. Their forecasts range from $109.00 to $162.00. On average, they expect Catalent's share price to reach $140.80 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for Catalent or view top-rated stocks among Wall Street analysts.

Who are Catalent's key executives?

Catalent's management team includes the following people:

• John R. Chiminski, Chairman & Chief Executive Officer (LinkedIn Profile)
• Alessandro Maselli, President & Chief Operating Officer (LinkedIn Profile)
• Thomas P. Castellano, Chief Financial Officer & Senior Vice President
• Kay Schmidt, Senior Vice President-Technical Operations
• Julien Meissonnier, Chief Scientific Officer & Vice President

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

Who are some of Catalent's key competitors?

Some companies that are related to Catalent include Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX), BeiGene (BGNE), Astellas Pharma (ALPMY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Genmab A/S (GNMSF), Shiseido (SSDOY), Genmab A/S (GMAB), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY) and UCB (UCBJF).
View all of CTLT's competitors.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.18%), Vanguard Group Inc. (10.76%), BlackRock Inc. (8.41%), State Street Corp (3.88%), Franklin Resources Inc. (3.17%) and Veritas Asset Management LLP (3.11%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano and Wetteny Joseph.
View institutional ownership trends for Catalent.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Thrivent Financial for Lutherans, Thrivent Financial for Lutherans, APG Asset Management N.V., Price T Rowe Associates Inc. MD, Baird Financial Group Inc., FMR LLC, and Franklin Resources Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano, and Wetteny Joseph.
View insider buying and selling activity for Catalent or view top insider-selling stocks.

Which institutional investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Amundi, BlackRock Inc., State Street Corp, JPMorgan Chase & Co., TimesSquare Capital Management LLC, Citigroup Inc., and Marshall Wace LLP.
View insider buying and selling activity for Catalent or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $137.27.

How much money does Catalent make?

Catalent has a market capitalization of $23.44 billion and generates $4.00 billion in revenue each year. The company earns $529 million in net income (profit) each year or $2.80 on an earnings per share basis.

How many employees does Catalent have?

Catalent employs 17,300 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

Where are Catalent's headquarters?

Catalent is headquartered at 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at (732) 537-6200 or via email at [email protected].